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Abstract
Many studies have explored phase-change contrast agents (PCCAs) that can be vaporized by an 
ultrasonic pulse to form microbubbles for ultrasound imaging and therapy. However, few 
investigations have been published demonstrating the utility and characteristics of PCCAs as 
contrast agents in vivo. In this study, we examine the properties of low boiling point nanoscale 
PCCAs evaluated in vivo, and compare data to conventional microbubbles with respect to contrast 
generation and circulation properties. In order to do this, we develop a custom pulse sequence to 
vaporize and image PCCAs using the Verasonics research platform and a clinical array transducer. 
Results show that droplets can produce similar contrast enhancement to microbubbles (7.29 to 
18.24 dB over baseline, depending on formulation), and can be designed to circulate for as much 
as 3.3 times longer than microbubbles. This study also demonstrates for the first time the ability to 
capture contrast wash-out kinetics of the target organ as a measure of vascular perfusion.
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Introduction
Since their early appearance in patent literature, ultrasonically-activated phase-change 
contrast agents (PCCAs) have been investigated to solve challenges in both diagnostic and 
therapeutic applications of ultrasound (Apfel, 1998). PCCAs provide a unique solution in 
that an externally-applied ultrasonic pulse of sufficient energy can be used to trigger a 
transition from a liquid state to a gas state – causing a significant change in the size, density, 
and compressibility of the particle located within tissue. Some of the earliest published 
studies demonstrated ultrasound-induced phase transition of superheated 
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dodecafluoropentane microdroplets in vitro and termed the phenomenon ‘acoustic droplet 
vaporization’ (Kripfgans et al., 2000; Miller et al., 2000). Continued studies showed the 
utility of this new class of agents in applications such as occlusion therapy, aberration 
correction, and cavitation enhancement (Kripfgans et al., 2002; Miller and Song, 2002; 
Miller et al., 2000).
Since these early experiments, the number of preclinical investigations using PCCAs has 
increased dramatically and expanded to applications spanning diagnostic/molecular imaging, 
drug/gene delivery, and tissue ablation (Lin and Pitt, 2013; Rapoport, 2012; Sheeran and 
Dayton, 2012; Wilson et al., 2013). These studies have shown that the ability to activate 
agents selectively in vivo can be useful in overcoming some of the limitations of 
conventional microbubble contrast agents. One of the most sought-after goals in PCCA 
literature has been to create agents with small initial size (in the liquid state) and longer 
circulation times compared to microbubbles in order to allow passive accumulation in solid 
tumors via the enhanced permeability and retention (EPR) effect (Campbell, 2006; 
Kopechek et al., 2013; Rapoport et al., 2009; Reznik et al., 2011; Sheeran et al., 2011b; 
Williams et al., 2013). Once vaporized to form microbubbles, the contrast present could be 
used to gain diagnostic information about the interstitial environment. Other studies have 
shown that vaporization of larger, microscale PCCAs may be useful for creating bubbles that 
become lodged in the vascular network and serve as references for phase aberration 
correction (Haworth et al., 2008). PCCAs may also be useful in ultrasound molecular 
imaging for eliminating the need to discriminate between circulating and molecularly 
targeted agents (Sheeran et al., 2013b). Once activated in a volume of interest, targeted 
agents will appear as stationary bubbles, while untargeted agents will clear from the imaging 
plane. Because the un-vaporized droplets remaining in circulation provide very low contrast 
relative to tissue, the level of molecular expression can be measured immediately. Some 
studies have demonstrated that the contrast from the newly-created bubbles can be used to 
aid in therapeutic goals (Couture et al., 2012; Zhang et al., 2010), and potentially with more 
control over spatial confinement of the effect compared to typical ultrasound contrast agents 
(Chen et al., 2013).
Perfluorocarbons have proven to be ideal compounds for use with phase-change contrast 
agents, given their low solubility in aqueous media, relatively high molecular weight, boiling 
points near physiologic temperatures, and an extensive history of use in medical imaging 
(Mattrey, 1994; Sheeran and Dayton, 2012). Despite a few studies demonstrating the 
imaging contrast produced by vaporized perfluorocarbon droplets (Kripfgans et al., 2005, 
2002, 2000; Williams et al., 2013), PCCAs have primarily been tested as tools to enhance 
therapeutic ultrasound. This preference most likely reflects the unique therapeutic 
opportunities provided by the dramatic change in agent properties with vaporization, as well 
as technological barriers that have, until recently, limited their use as diagnostic agents.
Although the theoretical expansion of perfluorocarbon droplets is 3 to 6 times their initial 
diameter, experiments have shown a size change on the order of 10 to 12 fold, as a result of 
the inward diffusion of dissolved gases from surrounding fluid (Kripfgans et al., 2000; 
Sheeran et al., 2011a, 2011b; Shpak et al., 2013). In order to produce ideal contrast-
providing bubbles for diagnostic vascular applications, droplet vaporization should produce 
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microbubbles on the order of 1 to 5 micrometers in diameter (similar to clinical formulations 
such as Definity; Lantheus Medical Imaging, Billerica MA, USA) to allow for high 
backscatter as well as safe passage through the microvasculature. As a result, the droplets 
must be on the order of 100 to 500 nm in diameter. One of the physical barriers to using 
PCCAs as contrast agents stems from scaling effects as droplet diameters are reduced to the 
low 100s of nanometers. For large droplets with boiling points near body temperature (such 
as dodecafluoropentane, boiling point 29°C), the droplets exist in a superheated state upon 
injection until they either spontaneously vaporize or are vaporized by ultrasound. However, 
as droplet size diminishes, the Laplace pressure increase resulting from interfacial surface 
tension elevates the boiling point (Rapoport et al., 2009; Sheeran et al., 2011b), creating 
what Lin and Pitt refer to as ‘artificial superheat’ (Lin and Pitt, 2013). At very small droplet 
sizes (such as 100s of nm in diameter), the boiling point elevation is substantial enough to 
limit the efficiency of vaporization and increase vaporization thresholds (Sheeran et al., 
2011b). This Laplace pressure influence is especially deleterious for diagnostic applications 
of PCCAs: it not only reduces the number of droplets that will vaporize at a given pressure, 
but may cause recently-vaporized bubbles to re-condense to the droplet state once the 
ultrasonic pulse has passed (Reznik et al., 2013) - reducing the number of contrast-providing 
bubbles.
One solution to reduce the vaporization thresholds may be to alter the characteristics of the 
vaporization pulse – such as altering pulse length and frequency. Previous studies have 
shown that under certain circumstances, pulse length appears to reduce the energy required 
for vaporization (Fabiilli et al., 2009; Lo et al., 2007; Williams et al., 2013). However, long 
pulse lengths will alter the bubble distribution as a result of rectified gas diffusion, bubble 
destruction, and fusion (Kang et al., 2014; Sheeran et al., 2013a; Shpak et al., 2013). These 
secondary effects and changes in bubble size distribution are likely to be unwanted for 
contrast applications, and may also cause unintended interactions with tissue. Alternatively, 
some of the earliest studies involving PCCAs demonstrated that increasing the ultrasound 
frequency reduced the pressure required to get a similar level of droplet vaporization 
(Kripfgans et al., 2000). This effect was confirmed in a number of separate studies (Fabiilli 
et al., 2009; Williams et al., 2013), and recently revealed to be the result of superharmonic 
focusing of nonlinear pulses that increases the negative pressure within the droplet (Shpak et 
al., 2014). However, for the purposes of contrast generation using sub-micron droplets, the 
frequency-dependence may not be a significant factor, since the focusing effect requires 
highly nonlinear pulses (i.e. high pressures) and appears to be relatively negligible for 
droplets much smaller than 1 micrometer in diameter at typical human diagnostic imaging 
frequencies.
Recent studies by our group have demonstrated that the increase in droplet vaporization 
threshold at small sizes can be circumvented by using perfluorocarbon species with lower 
boiling points, such as decafluorobutane (DFB, boiling point −2°C) and octafluoropropane 
(OFP, boiling point −37°C) (Sheeran et al., 2012, 2011a, 2011b). Because the critical 
temperatures of these compounds are much closer to body temperature than higher boiling 
point PFCs, the vapor bubbles formed from activation are less likely to re-condense due to 
Laplace pressure or the compressional half-cycles of the ultrasound pulse. Though a tradeoff 
exists between sensitivity to ultrasound (i.e. vaporization threshold) and general droplet 
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thermal stability, the droplet emulsions can be ‘tuned’ to provide an ideal balance for each 
application by mixing perfluorocarbon species (Kawabata et al., 2005; Sheeran et al., 2012). 
Previous studies have shown that condensation techniques can be used to generate stable 
sub-micron droplets that vaporize to bubbles of ideal size for contrast imaging and that these 
droplets can be activated at pressures available on typical diagnostic ultrasound machines 
(Sheeran et al., 2013a, 2013b, 2011a).
To our knowledge, no studies in the literature have explored the development of real-time 
diagnostic contrast-enhancement sequences based on PCCAs, although some studies have 
been published demonstrating both activation and imaging from a single imaging transducer 
(Couture et al., 2012; Sheeran et al., 2013b). As contrast agents, PCCAs require unique 
ultrasound pulse sequences to optimize diagnostic information. While other approaches are 
possible, perhaps the simplest is an image/activate/image sequence where the first imaging 
state is used to gather a pre-activation measurement and the second used to assess the level 
of contrast generated from an activation state. In the initial liquid state, pre-activation 
imaging must occur at pressures low enough to avoid droplet activation. When activation is 
desired (either at intervals or user-triggered), activation should cover the area of interest 
(pre-designated or operator-designated) and produce droplet vaporization as quickly as 
possible in the plane or volume – likely through focused pulses to minimize activation 
elsewhere. For the final imaging state, the imaging pressures must be low enough to not 
cause further droplet vaporization, and to not disrupt the bubbles produced (unless this is 
desirable). This post-activation imaging state must also occur quickly enough after the 
activation to capture contrast before it leaves the imaging plane, although this timing may be 
more flexible for droplets that are stationary (such as targeted droplets or those in tissue 
rather than vasculature). Clinical ultrasound scanners typically do not allow the level of 
pulse sequence customization required to create ideal PCCA-based contrast imaging without 
manufacturer research agreements. A new generation of highly-customizable ultrasound 
research platforms made by companies such as Verasonics (Redmond, WA, USA) and 
Cephasonics (Santa Clara, CA, USA) have allowed researchers to overcome these 
technological barriers and explore new imaging and processing techniques.
In this study, we use the Verasonics ultrasound platform to develop a custom PCCA-based 
diagnostic imaging sequence where both activation and imaging are accomplished using a 
single diagnostic linear array probe at ultrasound conditions at or near FDA guidelines for 
diagnostic imaging (Barnett et al., 2000). By controlling pulse timing, focusing, and 
pressure, we capture the contrast enhancement provided by PCCAs. Using the rodent kidney 
as a vascular target, we demonstrate the ability to evaluate both circulation and wash-out 
kinetics as a function of perfluorocarbon boiling point, and illustrate the considerations 
necessary to develop optimal sequences for PCCA contrast enhancement.
Materials and Methods
Contrast Agent Preparation
Perfluorocarbon microbubbles and phase-change contrast agents were prepared using 
techniques described in detail previously (Sheeran et al., 2012). The microbubbles and 
PCCA precursor microbubbles were encapsulated in a phospholipid cocktail consisting of a 
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9:1 M ratio of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-methoxy(polyethylene-glycol)-2000 (DSPE-PEG2000). 
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL, USA). The excipient 
solution consisted of a 16:3:1 ratio of phosphate-buffered saline (PBS), propylene glycol, 
and glycerol, producing a total lipid concentration of 1 mg/mL. Both control microbubble 
samples and PCCA precursor microbubbles were generated by adding 1.5 mL of the lipid 
solution to a 3 mL glass vial and gas-exchanging the headspace with either decafluorobutane 
or octafluoropropane gas (Fluoromed, Round Rock, TX, USA) prior to bubble formation via 
a standard mechanical agitation technique (Vialmix, Bristol-Myers-Squibb, New York, NY, 
USA).
To form PCCAs from decafluorobutane and octafluoropropane, a microbubble condensation 
technique was used to convert precursor bubbles (formed as described above) to the liquid 
state (Sheeran et al., 2012, 2011a). Briefly, the vials of microbubbles with cores composed 
of DFB or OFP were submerged in an isopropanol bath maintained at a temperature between 
−8°C and −10°C and swirled gently for approximately 2 minutes. The vials were then 
connected to an adjustable air-pressure source and the headspace pressure increased until a 
change in emulsion consistency indicating condensation was observed. For DFB samples, 
condensation was generally observed due to temperature alone, while OFP samples required 
on the order of 40–50 psi (275–350 kPa) to achieve condensation as a result of a much lower 
boiling point. Samples were stored at 4°C for a maximum of 5 hours prior to use for DFB, 
and a maximum of 2 hours for OFP to avoid variation as a result of thermal instability.
Microbubble size distributions were obtained by measuring 2 µL of microbubble emulsion 
with an Accusizer 780A (Particle Sizing Systems, Santa Barbara, CA, USA), and statistics 
averaged for 3 independent microbubble vials to obtain a representative distribution and 
concentration. PCCAs formed from condensed microbubbles were sized by using a 
NanoSight NS500 (Malvern Instruments Inc., Westborough, MA, USA) capable of 
measuring both size distribution and concentration of sub-micron particles. The NanoSight 
was used to capture six 30-second recordings at a temperature of 23.3°C for each sample 
with all other settings at default values. DFB and OFP droplet samples were diluted 1/200 in 
PBS prior to sampling. Measurements produced from each of the six recordings were 
averaged to produce a representative size distribution and concentration for each sample, and 
the process repeated for a total of 3 samples of both DFB and OFP droplets.
Droplet Imaging and Activation Pulse Sequence
All imaging and droplet activation was performed using a fully customizable Verasonics 
research ultrasound platform (Verasonics, Redmond, WA, USA), equipped with an ATL 
L12-5 38mm 192-element linear array probe (Phillips, Andover, MA, USA). The transducer 
was calibrated in the free-field using a needle hydrophone (Onda HNA-0400, Sunnyvale, 
CA, USA) in degassed water. The center 128 elements of the transducer were used for all 
imaging and activation. The Verasonics hardware was controlled by MATLAB (The 
MathWorks, Natick, MA, USA) scripts, which allows for simple customization of acoustic 
parameters. Three different sequences were developed: One for B-mode (anatomical) 
images, another for droplet activation, and a pulse inversion approach (Simpson et al., 1999) 
Sheeran et al. Page 5













for contrast-specific imaging. The output of the transducer in each imaging mode was 
controlled by adjusting the output voltage of the Verasonics hardware using MATLAB 
scripts.
B-mode—For B-mode anatomical imaging, a plane-wave coherent angular compounding 
approach (Montaldo et al., 2009) was implemented by delivering 9 MHz, 1-cycle sinusoidal 
pulses from the ATL L12-5 transducer. The final B-mode images were formed by 
compounding the envelope detected and beamformed RF signal from 7 transmit-receive 
frames in which the transmit beam was electronically steered at even angular intervals 
between the axial and lateral dimensions of the transducer (from −18° to 18°). The 
beamforming and compounding were performed by Verasonics reconstruction algorithms.
Pulse-inversion—For contrast-specific imaging, a similar coherent angular compounding 
approach as above was used in which the acquisition at each angle consisted of the RF 
addition of echoes received from sequential 4.5 MHz, 1-cycle pulses delivered 180° out of 
phase. The initial positive pulse was followed by a negative pulse after an interval of 105 µs, 
and each image was constructed from the compounding of all angles. The acquisition time 
between angles was 205 µs, and the final images were captured at a rate of 10 Hz. The 
number of compounding angles was reduced to 3 (−18°, 0°, 18°) in order to speed up the 
data transfer rate and reduce reconstruction time. The Verasonics was set to receive at 9 
MHz nominally, although no secondary filtering was performed to further isolate the 2nd 
harmonic component.
Activation—Droplet activation was achieved by a series of electronically focused and 
steered 5 MHz, 2-cycle sinusoidal pulses. The use of focused pulses allowed activation only 
within the region of the beam where pressures were highest – limiting unwanted activation 
elsewhere. In these studies, the area of activation was set to a rectangular region of interest 
(ROI) within the lateral width of the transducer. Focused pulses were delivered uniformly 
within this region by setting the lateral and axial spacing between each pulse to cover the 
ROI. The pulses were delivered in a raster-scan style along the rows from left to right, 
starting with the deepest row in order to prevent shadowing by bubble clouds produced early 
in the sequence. Inter-pulse delay was set to 50 µs (near the limit of the Verasonics 
hardware) in order to activate within the ROI as quickly as possible.
Combined Imaging/Activation Sequence—B-mode imaging was first used as an 
anatomical reference to locate and align the kidney with the activation ROI. Once the kidney 
was positioned in the desired location, B-mode images of the final kidney placement were 
captured and stored offline before switching to pulse inversion and droplet activation modes 
(Figure 1). Kidney motion due to breathing could result in droplet activation in a plane not 
aligned with the imaging plane, and therefore a two-trigger structure was developed to 
ensure alignment between activation and imaging planes. Kidney appearance and motion 
was monitored during the free imaging state, and upon completion of the previous breathing 
cycle, the operator triggered the pre-activation imaging state. In this state, 10 frames were 
collected at a frame rate of 10 Hz and then the system returned to a free imaging state to 
align with breathing motion prior to activation. Once the animal breathing motion ceased, a 
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second trigger transitioned the machine to the droplet activation sequence. After a 500 µs 
delay to switch the Verasonics hardware to the activation voltage, focused activation pulses 
were delivered as described above, completing the entire activation sequence on a short 
timescale relative to respiratory motion. Upon completion of the last focused pulse, a delay 
of 1.2 ms allowed the Verasonics hardware time to return to imaging output levels. After this 
pause, the machine entered a post-activation imaging state and collected 100 images at a rate 
of 10 Hz for droplet groups and 10 images at a rate of 10 Hz for microbubble groups. Data 
were transferred to the PC controlling the Verasonics after both the pre-activation and post-
activation captures for offline analysis. The final design choices for the imaging and 
activation states both in vitro and in vivo are reflected in Table 1.
In Vitro Verification
In vitro verification of the droplet activation sequence was performed in an acrylic-walled 
water bath that contained 4.7 L of degassed water maintained at 37°C by circulating warm 
water through submerged copper tubing. The transducer was angled to reduce direct 
ultrasound reflections during droplet activation studies. DFB droplets were dispersed in the 
water to a concentration of approximately 107 droplets/mL, and the water was stirred 
between experimental runs to redistribute the agents.
Based on preliminary studies, the Verasonics output voltage was set to 18V for all imaging 
sequences (Table 1). Hydrophone measurements of the spatial pressure distribution resulting 
from the focused pulses were gathered to correlate with images of microbubble clouds 
generated. The hydrophone was stepped through the transducer’s lateral-axial plane at 0.1 
mm intervals using a three-axis motion stage (Newport XPS-RC, Irvine, CA, USA). The 
maximum peak negative pressures were recorded, and the pressure distributions (beam 
profiles) were analyzed in MATLAB and combined to form a composite beam map.
At a nominal output voltage of 18V peak-to-peak, the maximum peak negative pressures 
were 482 kPa and 649 kPa for B-mode and pulse-inversion imaging, respectively. These 
pressures occurred at a depth of 1.5 cm for B-mode and 1.15 cm for pulse-inversion. As both 
imaging states were implemented with plane wave transmits, the pressure field was 
relatively uniform compared to a focused-wave approach. During focused activation pulses, 
the peak negative pressure was 3.0 MPa at a focal depth of 0.5 cm. Due to the elevational 
lens, pressure increased with increasing depth to a maximum peak negative pressure of 4.8 
MPa at 1.4 cm.
Pulses were delivered at even spacing (user specified) within a rectangular region of interest 
extending laterally from −6 mm to 6 mm relative to the center of the transducer face and 
axially from 5 to mm 14 mm. The multi-angle coherent plane-wave compounding with pulse 
inversion script described above was used to image the microbubble clouds generated in 
vitro by droplet activation following the application of focused ultrasound (2 cycles at 5 
MHz) in the presence of DFB. Results from these tests were used to set the axial and lateral 
activation pulse spacing for in vivo studies based on the assumption that pulse pressures and 
spacing adequate to activate DFB in vivo would produce even greater activation of OFP 
droplets – ensuring the ability to measure both agents.
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Fischer 344 rats (Charles River laboratories, Wilmington, MA, USA) were used in this study 
and protocols approved by the University of North Carolina School of Medicine’s 
Institutional Animal Care and Use Committee were followed. Three groups were included in 
the study: DFB droplets (N = 7), OFP droplets (N = 6), and microbubbles (N = 6). Animals 
in the microbubbles group were administered DFB microbubbles (the same precursors used 
to form DFB droplets). All rats were selected based on similar size (~150 g) and age to 
reduce experimental variation. Rats were anesthetized with 2.5% inhaled isoflurane mixed 
with room air and their body temperature was maintained using a controllable heating pad. 
A 24-gauge catheter was inserted into the tail vein for the administration of the agents. The 
abdomen was shaved and further depilated using a chemical hair remover, and the area to be 
imaged was coupled to the transducer with water-based acoustic gel.
B-mode imaging was used to locate the kidney within the abdomen. The transducer was 
moved laterally, axially, and elevationally by a motion stage (Model UTS150PP, Newport-
Irvine, CA, USA) until the kidney (transverse plane) aligned with the location of the 
activation ROI, and anatomical images were then captured. Prior to the injection of contrast 
agents, the Imaging/Activation program was used to capture agent-free baseline images.
Contrast agents were delivered as single 120 µL bolus doses injected manually followed by a 
flush of sterile saline, similar to a previous study in mice with DFB droplets (Chen et al., 
2013). Based on the contrast agent size distribution and concentration measurements (see 
Results section), each bolus consisted of 60 µL of contrast agents diluted in 60 µL of saline 
for an approximate initial blood plasma concentration of 3.99×107 #/mL, 8.42×108 #/mL, 
and 1.86×109 #/mL for control microbubbles, DFB droplets, and OFP droplets, respectively. 
Next, the pre-activation and post-activation frames were captured using the imaging/
activation sequence every 3 minutes for 19 minutes, starting at 1 minute after the injection 
for the DFB and OFP groups, and every 2 minutes for 15 minutes, starting 1 minute after the 
injection for the microbubble group. Animal breathing was monitored closely after the 
injection and for the remainder of the experiment. The dose of isoflurane was adjusted 
depending on the breathing rate of the animal.
In Vivo Activation Sequence Parameters
Based on the results of the in vitro verification experiments, a lateral spacing between pulses 
of 0.85 mm (50% of the measured lateral FWHM) and axial spacing of 1.5 mm (500% of the 
approximate axial FWHM). The area of activation was set to a rectangular region spanning 3 
mm to 12 mm axially and from −6 mm to 6 mm laterally relative to the center of the 
transducer. The change in the axial window between in vitro and in vivo studies was made in 
order to ensure the region covered the entire kidney region in this imaging orientation. This 
combination of ROI and pulse spacing resulted in 90 focused pulses spaced evenly across 
the region delivered at a rate of 20,000 pulses/s. Transducer output voltage was set to 18V 
for all imaging sequences, but increased to 30V during the activation sequence to counteract 
the effects of tissue attenuation. This translated to a free-field peak negative pressure (not 
accounting for tissue attenuation) of 482.3 kPa and 648.8 kPa during B-mode and pulse-
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inversion imaging, respectively (Table 1). The increase in activation voltage resulted in a 
free-field peak negative pressure of 8.3 MPa (at an axial depth of 1.1 cm).
Data Analysis
Custom MATLAB scripts were used to analyze the pulse inversion data captured with the 
Verasonics. The output image data (envelope-detected and beam formed) was square root-
compressed, so the pixel values in all the frames were squared to obtain the linear beam 
formed voltage data. In order to analyze the contrast properties within the kidney, reference 
images were normalized and converted to the decibel scale for visualization. Regions-of-
interest (ROIs) were placed manually in the reference image and applied to all frames of the 
underlying (linear) data set. In cases where shadowing in the images was present, ROIs were 
drawn to avoid inclusion of the affected pixels. The average pixel value and standard 
deviation inside the ROI were calculated on each frame of the voltage data.
Contrast Enhancement Measurement—The degree of contrast enhancement was 
measured by comparing the contrast images with the agent-free baseline in the following 
sequence. An ROI was placed around the region of highest activation within the kidney in 
the first post-activation frame (or post-injection, in the case of microbubbles). The mean 
pixel value was computed for each frame of the entire data set (agent-free baseline, pre-
activation, post-activation). For groups that were administered microbubbles, the data set 
consisted of only the agent-free baseline images and the post-injection images. The agent-
free baseline value for each animal was calculated by averaging the ROI values from the 10 
agent-free baseline images. The mean pixel value of each frame after administration of the 
contrast agents was normalized to the agent-free baseline value and converted to decibel 
scale to arrive at a dB increase in contrast relative to agent-free baseline.
Percentage Filled Measurement—To measure spatial aspects of contrast enhancement, 
an ROI was drawn around the entire border of the kidney and the mean and standard 
deviation of the pixel values within the ROI calculated. At each of the contrast measurement 
time points, the percentage of pixels that exceeded the mean value of the agent-free baseline 
by at least 3 standard deviations was calculated as a measure of the spatial coverage of the 
newly generated contrast. Because some pixels in the agent-free case exceed this threshold 
(due to nonlinear tissue signal), the ‘percent filled’ value was adjusted by subtracting the 
percentage obtained in the agent-free case. Due to the fundamental physics of ultrasound 
speckle, as well as the vascular structure of the kidney, the percent filled value should 
naturally reach a maximum value less than 100.
Half-Life Measurements—Using the contrast enhancement measurements described 
above, the decrease in the contrast captured with each sequential data set was analyzed to 
obtain contrast half-lives and quantitatively compare the longevity of agent circulation. The 
contrast enhancement values of each data set were normalized to the maximum value 
obtained at the 1 minute time point, and the normalized data for each animal was fitted with 
an exponential of the form
Sheeran et al. Page 9














where t is the time in minutes after injection, and βh is the rate of decay. In this fit, any time 
points were excluded where the mean contrast enhancement captured by the post-activation 
imaging was not significantly increased compared to the pre-activation imaging. These were 
excluded due to the fact that the mean contrast should return to zero for the exponential. The 
contrast measurements capture the maximum signal due to contrast agent enhancement, but 
once contrast is no longer being produced, this measure will capture the variation in the 
noise and produce a non-zero value at late time points.
Wash-out Rate Measurements—To measure the rate of contrast clearance from the 
imaging plane post-activation, the contrast enhancement measurements were clipped to the 
maximum value (with breathing noise removed) and fit with an exponential curve of the 
form
(Eq. #2)
where βw is the wash-out rate, tmax is the time at which the maximum contrast occurred, and 
dBmax is the maximum contrast enhancement produced.
Results
Contrast Agent Sizing and Concentration
The averaged distribution of DFB microbubbles, which were used as control agents 
throughout this study, had a mean diameter and variation of distribution of 1.00 ± 0.89 µm, 
with a mode size of 0.62 µm, and a total concentration of 6.57×109 ± 0.84×109 bubbles/mL 
(N = 3) (Figure 2a). Reproducibility between samples was high, with the standard deviation 
in the mean of 0.06 µm, and standard deviation in the mode of 0.01 µm (N = 3). Similarly, 
the precursor microbubbles used to make OFP particles had a mean diameter and variation 
of distribution of 1.03 ± 0.66 µm, with a mode size of 0.61 µm. OFP microbubbles had a 
higher mean concentration of 8.50×109 ± 1.4×109 bubbles/mL (N = 3) compared to DFB 
microbubbles, but not significantly so (p = 0.16, Student’s two-sided t-test).
The representative distributions obtained by averaging all 3 samples of each type of droplet 
(Figure 2b) produced a mean diameter and distribution variation of 166 ± 59 nm for DFB, 
with a mode size of 141 nm, and a total concentration of 13.88×1010 ± 6.58×1010 
droplets/mL, while OFP produced a mean diameter and distribution variation of 154 ± 64 
nm, with a mode size of 110 nm, and a total concentration of 30.61×1010 ± 9.65×1010 
droplets/mL. Reproducibility between samples was high, with the standard deviation in the 
mean less than 3 nm for both OFP (N = 3) and DFB (N = 3). Similarly, mode size of the 3 
samples for each droplet type had standard deviations less than 12 nm. A Kolmogorov-
Smirnov test showed that the smaller size distribution of OFP droplets was statistically 
significant compared to DFB (p < 0.001), which agreed with Student's two-tailed t-test 
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evaluation of the measured mean (p = 0.03) and mode (p<0.01) values for the two droplet 
types. OFP droplets had a nearly significant increase in concentration compared to DFB (p = 
0.07), similar to the microbubble concentration results. The smaller mode and mean 
diameters of the OFP samples can be expected based on ideal gas laws, which predict a 
greater size-dependent factor of conversion for OFP than DFB (Evans et al., 2006; Sheeran 
et al., 2014, 2011b). Given that the peak in the DFB microbubble distribution occurred at 
0.62 µm and at 0.61 µm for OFP, an assumption of ideal conversion between the gas and 
liquid states suggests a conversion factor of 5.57 ± 0.33 for OFP and 4.41 ± 0.37 for DFB.
Droplet measurements produced higher concentrations than microbubble measurements, 
which requires further discussion. A small increase in concentration is expected as a result 
of the reduction in volume of each PFC agent converting to the liquid state, although in 
theory this should only result in a decrease in total emulsion volume on the order of 5–10 µL 
– not explaining the order-of-magnitude difference between droplets and bubble 
measurements. We hypothesize that the discrepancy is due to the differences in the 
equipment used to measure the agents. Specifically, the Accusizer is not sensitive to objects 
smaller than 500 nm in diameter – although the lower limit of the microbubble distribution 
(Figure 2a) clearly indicates that there must be agents present in this range. This unmeasured 
content suggests the actual concentration in the microbubble samples is likely higher than 
the measurements provide. Additionally, empty vesicles present in the solution as a result of 
the phospholipid preparation may increase the measured concentration to some degree. In 
previous studies, measurements of the pure phospholipid solution showed a small number of 
particles were present on the order of 100 nm (Sheeran et al., 2011a). Future studies are 
needed to determine the degree to which sub-micron concentration measurements are 
skewed by these vesicles. Regardless, these discrepancies highlight inherent challenges in 
measuring nanoscale and microscale distributions in order to compare performance.
In Vitro Verification
Testing within an imaging field measuring 1 cm2 at a depth of 1 cm in a water bath 
maintained at 37°C and containing a concentration of approximately 107 DFB droplets/mL 
demonstrated a correlation between the focal pressures and the sizes of individual 
microbubble clouds generated by droplet activation (Figure 3). At the in vitro imaging and 
activation output settings (see Methods section), vaporization of DFB droplets was not 
observed prior to triggering the focused activation pulses, indicating pressures were low 
enough to eliminate unintended vaporization. This matches previous in vitro measurements 
showing that efficient DFB activation at frequencies near 5 MHz requires pressures on the 
order of 2 MPa or greater (Sheeran et al., 2013a).
During focused activation pulses, the focal zones as well as the maximum peak negative 
pressures achieved within these zones differed depending on the focal depth (Figure 3a) as a 
result of the elevational lens. Accordingly, the sizes of the microbubble clouds differed as a 
function of the focal depth (Figure 3b). Converting the output peak negative pressures to 
Mechanical Index (defined as the PNP in MPa divided by the square root of the center 
frequency in MHz (Apfel and Holland, 2014)), the maximum MI in the imaging state was 
0.3, and the maximum MI in the activation state was 2.1. It is important to note that a 
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mechanical index of 2.1 is higher than the current regulatory limits of diagnostic ultrasound 
output (MI = 1.9). In this study, it is evident that DFB droplets can be activated at ultrasound 
pressures lower than MI = 1.9. For example, in Figure 3b at a focal depth of 0.5 cm, bubble 
clouds are produced at MI = 1.3, although they are much smaller than those produced using 
higher pressures.
Even in this relatively small acoustic field, differences in the shapes of the focal zones and 
associated microbubble clouds can be discerned, demonstrating the consequence of 
electronically steering the focal beam to reach more lateral targets. As depth increases, the 
beam angle produces a slightly rotated bubble cloud. Additionally, the elevational lensing 
results in an increase in the microbubble cloud size with depth. When focused pulses are 
placed sparsely, such as a lateral separation of 6 mm and axial separation of 4.5 mm, 
contrast can be generated in isolated regions with no overlap (Figures 3a and 3b). The 
accumulation of many individual microbubble clouds can fill a region of interest with 
bubbles (Figures 3c and 3d). Differences in the individual microbubble cloud shapes and 
sizes as a function of their location in the acoustic field can be appreciated if the activating 
foci are spaced at 1.2 mm laterally (70% of the measured lateral full-width-half-max) and 
2.1 mm axially (700% of the approximate axial full-width-half-max) (Figure 3c). However, a 
more uniform vaporization field of bubbles can be generated if the activating foci are spaced 
closer at 0.43 mm laterally (25% of the full-width-half-max) and 0.75 mm axially (250% of 
the approximate axial full-width-half-max) (Figure 3d). Although this results in a visually 
confluent region of contrast, it also indicates that the vaporization pulses may be interacting 
with the bubbles produced from previous pulses.
In Vivo Acoustic Parameters
To transition to in vivo verification, a lateral spacing between pulses of 0.85 mm (50% of the 
measured lateral FWHM) and axial spacing of 1.5 mm (500% of the approximate axial 
FWHM) was chosen within the 1.08 cm2 activation region (see Methods section) in order to 
ensure bubble clouds generated from DFB droplets did not overlap significantly and 
minimizing exposure of existing bubbles to the higher energy activation pulses. These 
represent distances in between the spacing presented in Figures 3c and 3d. In our setup using 
a linear array transducer with an elevational lens, the pulse pressures increased with depth up 
to the elevational focus. However, this will not necessarily be the case in vivo, as frequency-
dependent attenuation diminishes the pulse pressure as a function of depth and frequency.
Initial in vivo investigations at the same pulse parameters used for in vitro verification were 
not capable of producing contrast from DFB droplets, although they proved sufficient to 
generate contrast from OFP droplets. In order to counteract tissue attenuation and aberration, 
transducer voltage was increased to 30V for the focused-wave activation state, but the plane-
wave imaging states remained at 18V. In order to estimate the actual in vivo pressures at this 
output voltage, the free-field pressures (see Methods section) were derated by a model 
assuming 3 mm of superficial soft tissue (attenuation coefficient of 0.6 dB/cm at 1 MHz) 
followed by kidney tissue (attenuation coefficient of 1.0 dB/cm at 1 MHz). The attenuation 
coefficients were scaled assuming a frequency dependence of 1.1 (α=α0f1.1) (Bamber, 2005, 
2002; Mast, 2000). With this model, the highest in vivo PNPs during the B-mode and pulse-
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inversion imaging states were 273.7 kPa (MI = 0.09) and 433.1 kPa (MI = 0.14), 
respectively (Table 2). During the focused-wave activation state the PNP was 3.7 MPa (MI = 
1.65) at a depth of 3 mm (the shallowest pulses near the start of the kidney region). At 10 
mm, where the kidney region of most of the test rodents ended, the PNP was 4.2 MPa (MI = 
1.89). The highest PNP was 4.5 MPa (MI = 2.01), occurring at a depth of 8.5 mm. The 
deepest focused pulses in the activation ROI, occurring at 12 mm, produced a PNP of 3.8 
MPa (MI = 1.70). Thus, the majority of the focused pulses occurred at mechanical indices 
below the regulatory limit of 1.9, although the pulses central to the kidney occurred at output 
levels slightly above MI = 1.9 as a result of the elevational focusing lens.
Contrast Enhancement Measurements
Given the differences in the size distributions of the three types of agents as well as the 
reported differences in concentrations, matching doses in a number-matched or volume-
matched manner is not straightforward. Matching the total number of agents per dose does 
not necessarily produce the same number of microbubbles in the imaging region, as droplet 
vaporization is fundamentally stochastic. Matching the volume that PFC occupies in the 
dose does not reflect the different state of microbubbles and PCCAs. To proceed with these 
preliminary in vivo demonstrations, we chose to use a constant aliquot volume from each 
sample, as the differences in concentration between OFP and DFB droplets were not 
statistically significantly. For microbubbles, this same aliquot was chosen with the 
assumption that the actual microbubble concentration was higher than reported (due to the 
differences in particle sizing equipment), and with the assumption that a higher droplet 
concentration may compensate for droplet-to-bubble conversion rate less than 100%.
With these experimental choices, contrast produced from microbubbles, DFB droplets, and 
OFP droplets was easily captured. For tests involving bubbles (no activation pulse), very 
little contrast signal (due to artifact) was present prior to injection (Figure 4). After injection, 
the relatively high dose of bubbles created a strong contrast signal that diminished at each 
time point until no contrast enhancement was observed (typically between minutes 11 and 
15). Similar to the microbubble tests, very little signal was present within the kidneys prior 
to PCCA injection (Figure 4). After injection of DFB droplets the kidneys produced similar 
contrast to the agent-free baseline, indicating agents were still in the liquid state and that 
few, if any, bubbles were present due to spontaneously vaporized droplets. OFP droplets, 
however, produced some ‘flashing’ contrast after injection during the pre-activation imaging 
sequences, indicating either spontaneous vaporization to bubbles while in circulation or 
activation of OFP droplets by imaging pulse pressures (see further discussion below). After 
the vaporization sequence was triggered at 1 minute post-injection, a high degree of contrast 
was present in the kidney for both DFB and OFP (Figure 4). DFB droplets created a distinct 
spatial pattern due to the spacing between the individual vaporization pulses. Subsequent 
imaging/activation sequences for DFB every 3 minutes up to the final time point at 19 
minutes showed a similar spatial pattern with a gradual decrease in the amount of contrast 
produced. For tests with OFP droplets, a high degree of uniform contrast was present 
throughout the kidney after the activation pulse was delivered. No spatial patterning was 
present, indicating a much higher degree of activation and bubble formation. In fact, at early 
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time points, the contrast present within the kidney was high enough to cause shadowing deep 
within the kidney that brightened as contrast washed out of the upper imaging plane.
Measuring contrast produced by the microbubble injections inside the ROI produced a 
steady level of contrast enhancement in the 1 second captures at each time point. Droplets, 
on the other hand, produced a distinct wash-out phase as the newly generated contrast 
diffused out of the imaging plane and into the rest of the kidney and circulatory system over 
the 10 to 20 seconds following the activation sequence. Characterizing the contrast 
enhancement relative to the agent-free baseline for all frames of the video capture produced 
a contrast wash-out curve at each major time point (Figure 5). Repeating this measurement 
at each major time point allows assessment of the change in the level of activation over time, 
which is directly related to the decay and clearance of the non-activated agents remaining in 
circulation. In these contrast wash-out curves, breathing motion manifests as dramatic drops 
in the measured value, as breathing causes translation into a neighboring imaging plane 
where fewer bubbles exist. In Figure 5, breathing motion artifacts have been manually 
removed to increase clarity.
Grouping the contrast enhancement results for each animal by agent type allows for further 
analysis illustrating the fundamental difference in the behavior of the agents. The maximum 
contrast present in animals prior to microbubble injection (N = 6) (representing the ‘noisiest’ 
frame in the agent-free video capture) was 0.19 ± 0.10 dB. After injection, microbubbles 
produced a high degree of initial contrast, with a mean value of 12.63 ± 3.64 dB at the 1 
minute time point (Figure 6a). Over the next 10 minutes, the contrast decayed quickly and 
returned to baseline levels by the 13 to 15 minute time points.
For the droplet groups, the pre-injection measurements were similar to the microbubble test 
group, with noise in the measurement on the order of less than 1 dB (Figure 6b). After the 
activation sequence, animals in the DFB test group (N = 7) produced a mean contrast 
enhancement at 1 minute post-injection of 7.29 ± 3.65 dB over the agent-free baseline. At 
each sequential time point, the ‘on-demand’ contrast from the activation sequence gradually 
decreased in magnitude, producing a mean contrast enhancement of 2.27 ± 0.92 dB at the 19 
minute mark that could be easily observed in the video sequence. In comparison to DFB 
droplets and microbubbles, activated OFP droplets produced a high initial contrast 
enhancement, with a mean value of 18.24 ± 3.14 dB at 1 minute post-injection. Similar to 
microbubbles, OFP contrast generated from each activation sequence decayed rapidly over 
the course of 19 minutes. At the 13 minute post-injection time point, contrast produced by 
OFP had a lower mean value (2.24 ± 1.19 dB) than DFB (3.49 ± 1.78 dB), suggesting the 
concentration in the bloodstream diminished much more rapidly than DFB. This matches 
prior in vitro experiments demonstrating relatively poor thermal stability of OFP droplets at 
37°C (Sheeran et al., 2012).
In all three agent types, the range of values in each group at early time points was high, 
likely due to differences in attenuation and aberration from animal to animal. These effects 
not only limit brightness of the contrast captured, but also diminish the ability to produce 
droplet vaporization at depth. In several of the DFB test cases, the appearance of the contrast 
varied spatially throughout the kidney, with high activation in the axial line central to the 
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transducer and reduced activation in the left and right extremities of the kidney. In most 
cases, these reduced regions of activation corresponded with visible acoustic shadowing 
from upper layers – highlighting the importance of coupling the transducer to the skin as 
well as possible for PCCA contrast studies.
To arrive at the contrast enhancement values in Figure 6, measurements were normalized to 
the mean value of the agent-free baseline images rather than the pre-activation images 
collected just before application of the vaporization sequence. This choice was based on 
preliminary studies showing that the pre-activation measurement of OFP agents was 
influenced by droplet vaporization (Figure 4 and 5b). Thus, normalizing to the pre-activation 
mean value would have the effect of under-reporting the actual contrast generated by OFP 
particles at early time points. As a result of this choice, it is possible for a systematic shift in 
the measurements to occur. It was noticed during testing that the mean value of the pre-
activation images at later time points post-injection did not always match the agent-free 
baseline. For example, while the agent-free baseline had a zero-mean value, at the 19 minute 
mark the pre-activation images of both DFB and OFP had a mean value on the order of 0.5 
dB (Figure 7a). In the agent-free baseline, the maximum ‘noise’ in the contrast measurement 
(the maximum value of the tissue signal in any frame compared to the mean of all frames) 
was 0.22 ± 0.08 dB for DFB and 0.22 ± 0.13 dB for OFP. At the 19 minute mark, this 
increased to a value of 0.44 ± 0.20 dB for DFB and 0.82 ± 0.33 dB for OFP (Figure 7b). 
Although this type of systematic shift could result from circulating microbubbles created by 
previous vaporization pulses, the small fraction of bubbles created by each sequence relative 
to the total blood volume, along with the short circulation time of the microbubbles suggests 
this is unlikely. Visually, the pre-activation captures at these later time points have the 
appearance of being completely free of contrast agents. We therefore hypothesize that this is 
a result of slight shifts in the imaging plane accumulating due to breathing motion over the 
test period. At the beginning of tests, the transducer was aligned with the most anechoic 
plane of the kidney, and so any shifts from this plane would result in a general increase in 
the mean tissue signal.
This bias in the measurements complicates the assessment of contrast enhancement in that 
the maximum dB level produced at each time point may not actually indicate an increase in 
contrast as a result of the vaporization pulses. Comparing the contrast produced in the 10 
frames just prior to activation with the 10 frames following activation statistically (student’s 
two-sided paired t-test) correlates well with visual assessment of whether an increase in 
contrast was produced by the sequence. For DFB, all 7 test subjects had a statistically 
significant increase in contrast at the 19 minute time point, indicating viable droplets were 
still present in circulation. For OFP, all subjects had a significant increase in contrast at 
minutes 1 through 10. However, the number of animals with increases in the contrast 
measurement dropped to only 3 out of 6 by the 16 minute mark, and 2 out of 6 by the 19 
minute mark. This highlights the difference in stability between choices of PFC: at the last 
time point tested, new contrast was being generated in all animals given DFB droplets, while 
OFP droplets had cleared from circulation in the majority of animals.
Figure 7b also shows important aspects of OFP performance at early time points. Due to the 
low vaporization thresholds of OFP and relative thermal instability, contrast is produced 
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even during the pre-activation imaging, manifesting as bright, temporary ‘flashes’ in the 
videos (Figure 4). This appears as spikes in the pre-activation contrast measurements (Figure 
5b). This may be due to a combination of spontaneously vaporized droplets as well as 
droplet vaporization due to the pressure of the imaging pulses. In previous in vitro studies, 
the vaporization threshold of microscale OFP droplets exposed to 8 MHz, 2 cycle pulses 
proved to be at peak negative pressures on the order of 0.5 MPa (Sheeran et al., 2012). Here, 
the imaging state reached estimated peak negative pressures in the tissue of 424.2 kPa, and 
so we hypothesize that this effect is primarily due to imaging pulses that exceed the 
vaporization threshold of large outlier droplets still in circulation at early time points. This is 
consistent with preliminary studies using lower imaging pressures, where OFP ‘flashing’ 
was not observed.
Half-life Measurements
By normalizing the contrast enhancement data to the maximum value, the circulation half-
life can be calculated with a mono-exponential fit described in Eq. #1 (Figure 8). Using this 
analysis, microbubbles had a mean decay rate of 0.22 ± 0.02 min−1, producing a mean 
circulation half-life of 3.26 ± 0.37 min. The minimum and maximum half-lives in the group 
were 2.77 min and 3.83 min, respectively. OFP droplets produced similar measurements as 
microbubbles, with a mean decay rate of 0.20 ± 0.06 min−1. The mean half-life of the group 
was 3.67 ± 0.37 min, with minimum and maximum half-lives in the group of 2.43 min and 
5.51 min, respectively. OFP half-lives were not statistically significantly different compared 
to the half-lives of the microbubble group (p = 0.4, student’s two-tailed t-test). DFB 
droplets, while initially showing lower contrast than the other two types of particles at the 1 
minute time point, produced a significantly slower mean decay rate of 0.07 ± 0.01 min−1. 
The mean half-life of the group was 10.84 ± 1.63 min, with minimum and maximum half-
lives in the group of 8.07 min and 13.02 min, respectively. DFB half-lives were statistically 
significantly different compared to both microbubbles and OFP droplets (p << 0.01).
Percentage of Kidney Filled
Up to this point, all analysis has been based on the mean value of an ROI placed in the area 
of highest contrast within the kidney, but analyzing the contrast production by other 
approaches further illustrates the differences between agents. One possibility is to calculate 
the percentage of pixels in the kidney as a whole that have exceeded a threshold defined by 
the agent-free case. This measurement takes into account spatial coverage of the contrast 
rather than overall intensity. Analyzing the data by this process with a pixel threshold of 3 
standard deviations above the mean of the agent-free baseline further reveals differences in 
performance between DFB, OFP, and microbubbles (Figure 9). Circulating microbubbles 
produced a mean of 45.11 ± 7.88 percent filled, while OFP produced a higher mean of 49.62 
± 5.97 percent filled compared to microbubbles (p = 0.19). DFB, though affording longer 
circulation time, produces a significantly lower mean of 15.69 ± 8.4 percent filled compared 
to both microbubbles and OFP droplets (p << 0.01). These data demonstrate that the contrast 
produced from phase-change agents can create more complete coverage of the target organ 
(OFP) or less (DFB) compared to microbubbles, depending on PCCA formulation, 
concentration, and activation pulse settings. Although not explored in depth here, this 
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One unexpected aspect of the wash-out curves captured in this study (Figure 5) is the 
appearance of two distinct phases. In the first phase, typically occurring in the first second 
following the vaporization sequence, the contrast within the ROI increases until it reaches a 
maximal value within 1 to 2 dB of the initial value. This increase may be partly due to 
contrast spreading from the spatial location of the peak pressures into neighboring regions. It 
may also be a result of bubble growth shortly after vaporization due to intake of ambient 
gases dissolved in the bloodstream (Kripfgans et al., 2000; Sheeran et al., 2011a, 2011b; 
Shpak et al., 2013). In the second phase, the contrast decays exponentially as it washes out 
of the imaging plane and into the rest of the bloodstream. The mechanisms that create this 
two-phase behavior require further investigation.
The exponential decay portion of these contrast curves affords a unique possibility to 
measure a wash-out rate of the vascular network in the imaging plane. Because contrast can 
be generated ‘on-demand’ with PCCAs and monitored in real-time, the clearance rate can be 
captured and used as an indication of perfusion. This is similar in concept to the destruction-
replenishment curves gathered in microbubble-enhanced ultrasound that have been utilized 
to measure tissue perfusion (Quaia, 2011; Wei et al., 1998). In destruction-replenishment, 
pressures near the current upper limit of diagnostic ultrasound are used to destroy the 
microbubbles in the imaging plane, followed by lower imaging pressures to capture contrast 
reperfusion. Conversely, with a PCCA sequence high pressures are used to generate contrast 
in the imaging plane rather than destroy it, and lower pressures used to capture wash-out 
rather than reperfusion.
As a simple demonstration, the wash-out curves produced 1 minute post-injection for DFB 
and OFP were fitted with the mono-exponential described in Eq. #2. The DFB group 
produced a mean wash-out rate of 0.17 ± 0.04 sec−1, while OFP produced a mean rate of 
0.13 ± 0.03 sec−1. The clearance rates of the two different agents were nearly statistically 
significant compared to each other (p = 0.08), which may be as a result of the differences in 
the droplet distributions. As DFB droplets are more thermally stable than OFP, it may be that 
large outlier droplets are present during activation and take longer to clear compared to OFP. 
Future studies are needed to compare clearance rate as a function of dose, pulse pressures, 
droplet size distribution, and droplet boiling point to determine possible sources of these 
differences. For instance, increased pressures and/or choosing droplets with lower 
vaporization thresholds increases the extent of vaporization in the elevational dimension as 
well, which may change the measured wash-out rate.
Although the wash-out characteristics here were captured after a single activation sequence 
spanning the entire region of interest and with similar droplet size distributions, there are 
many implementations that could be explored in future studies. Beyond measuring 
differences in perfusion as a function of droplet size, one could create sparse pockets (i.e. 
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from single pulses) at desired locations and measure the dissipation as an indication of the 
underlying vasculature. This differs fundamentally from microbubble destruction-
replenishment approaches, where microbubbles in the entire imaging volume are destroyed 
and the measurement depends on the re-perfusion from all neighboring vascularized tissue. 
It may be much simpler to apply PCCA wash-out measurements to 3D imaging than 
destruction-replenishment, since a single bolus could be created in the center of the volume 
of interest and then be tracked as it dissipates. In larger vessels, PCCAs could be vaporized 
upstream using electronic steering and the microbubble bolus tracked as it passes a target 
site - allowing measurement of both flow velocity and flow dynamics. This may be a very 
desirable approach to theranostic applications, such as targeted clot break-up - where a site 
is evaluated using PCCA perfusion and then treated.
Finally, it is worth noting that in microbubble destruction-replenishment, pressures 
necessarily must be high enough to cause bubble collapse and signal extinction. In PCCA 
wash-out curves, however, high pressures are not necessarily required to generate contrast 
and monitor the wash-out because it is not a requirement to destroy the contrast agents. The 
pressure and pulse spacing used here are not optimized for OFP, and it may be possible to 
accomplish these measurements with significantly less energy delivered into tissue. 
Furthermore, refinements in droplet properties (size distribution, vaporization thresholds) 
and dosing may produce a balance that minimizes interaction with vasculature.
Limitations and Future Directions
Adverse Reaction Monitoring—In these studies, no animals displayed visible 
symptoms of distress or breathing difficulties during the tests or in the post-test monitoring 
(typically 1 – 2 hours following regaining of consciousness). This suggests the bolus doses 
were well tolerated, although further dose dependence tests that include cardiac monitoring 
are needed. As a whole, few dose dependence studies are available for PCCAs – especially 
at nanoscale sizes. In a study with microscale PFC droplets, Zhang et al. observed 
respiratory distress and blood chemistry changes in a canine model at doses of 2×109 
droplets/kg, and a dose of 3×109 droplets/kg (total PFC dose of 0.2 g/kg) was fatal to the 
animals (Zhang et al., 2011). Here, much higher doses were administered to the rodents per 
kg – 5.55×1010 droplets/kg for DFB droplets and 1.22×1011 droplets/kg for OFP droplets, 
but the size distributions an order of magnitude smaller in diameter produced a substantially 
lower total PFC dose of approximately 2.12×10−4 g/kg for DFB droplets and 3.75×10−4 g/kg 
for OFP droplets.
One of the most important aspects of PCCA vaporization is the possibility of bioeffects to 
the surrounding vascular network and tissue (Samuel et al., 2012). This may be desirable in 
some applications of drug delivery and tissue ablation. However, for the purposes of 
diagnostic/molecular imaging minimal interaction with tissue is vital. Studies are ongoing to 
assess damage from vaporization of volatile PCCAs and determine the dependence on 
droplet formulation, size distribution, and pulse parameters.
Influence of Activation on Half-Life Measurements—One aspect that is not well-
understood is to what degree the activation of PCCAs at each time point influences future 
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measurements. We have assumed in this study that the activation/imaging plane of the 
kidney represents a small fraction of the overall blood space that PCCAs occupy. However, 
it is possible that the actual contrast half-lives are higher than measured here due to the fact 
that each activation sequence removes a fraction of the viable droplets. Regardless, the 
results demonstrate that PCCAs generally have longer circulation properties than 
microbubbles. Even the most volatile PCCA explored in literature to date - OFP droplets 
(PFC boiling point of −36.7°C) - exhibited a virtually identical clearance rate to 
microbubbles, while DFB droplets had more than three times the measured contrast half-life 
that microbubbles exhibited. This study also demonstrates that PCCAs at relatively similar 
doses can produce similar contrast properties as clinical microbubble formulations, which 
matches previous studies exploring the acoustic properties of bubbles produced from PCCAs 
(Reznik et al., 2014).
Future Implementation—In this preliminary in vivo demonstration of PCCA contrast 
production, a plane-wave approach to imaging was chosen to facilitate speed in imaging and 
data transfer. In early studies, plane wave transmits allowed investigation of the period 
following activation on a short timescale (frame rates near 1 kHz) – but it was found that the 
wash-out kinetics allowed a much slower frame rate to sufficiently capture contrast wash-
out. The final frame rate chosen (10 Hz) leaves much room to improve the imaging quality 
by developing a focused-wave imaging approach. This may allow better visualization of the 
unique contrast properties of PCCAs and how they depend on the underlying vascular 
structure.
It is worth noting that portions of this study (free imaging for alignment and breathing 
motion monitoring) were captured and displayed in real-time on the Verasonics hardware, 
but that the actual data captures were not displayed in real-time. This was primarily due to 
the ultimate intent of offline analysis. However, real-time implementation of the entire 
sequence could be accomplished easily on the Verasonics with simple changes to the scripts 
- allowing one to trigger vaporization and visually monitor the contrast enhancement. This is 
conceptually very similar to microbubble destruction-replenishment sequences (except for 
the activation sequence design), which are currently implemented on pre-clinical and clinical 
scanners. The measured clearance in the rodent kidney in this study suggests that imaging 
rates as low as 10 Hz are sufficient to capture the contrast dynamics of these formulations, 
which is well within the capabilities of current systems for both plane wave and focused 
imaging approaches.
The performance of the two different PCCA formulations was compared with set imaging 
and activation parameters in order to evaluate relative differences when the same acoustic 
settings are chosen. In reality, the pulse sequence should be designed around formulation 
and intended use (therapeutic vs. diagnostic) of the PCCA. Some of these considerations are 
highlighted in a recently published investigation performed in parallel to this one (Puett et 
al., 2014). Here, the acoustic choices resulted in over-activation and unintended vaporization 
during imaging for OFP droplets, and under-activation of DFB droplets as a result of the 
drastic differences in droplet boiling point. For OFP, future sequences will require lower 
imaging pressures and adjustment of pulse pressure and spacing, whereas for DFB it is 
likely that higher pressures can be used on imaging and activation (or, alternatively, closer 
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activation pulse spacing). Because of elevational focusing from the transducer used, the peak 
negative pressures varied highly with depth. This resulted in activation pulses that were 
lower than the regulatory limits (MI = 1.9) as well as some that exceeded these limits. It is 
evident from the images both in vitro (Figure 3) and in vivo (Figure 4) that activation of 
DFB and OFP can be accomplished at PNPs below these limits – as contrast is produced at 
superficial locations where the measured pressures do not exceed these limits. This is 
consistent with previous in vitro studies showing that DFB droplets can be activated 
optimally with short pulses that do not exceed MI = 1.9 (Sheeran et al., 2013a). In future 
studies, implementing the entire pulse sequence within regulatory limits might be 
accomplished by using 1.5 or 2D arrays, or by simply adjusting the output pressure as a 
function of axial depth through transmit apodization or output voltage.
Conclusions
In this study, we have demonstrated that custom imaging and activation sequences can be 
developed to produce and capture contrast from perfluorocarbon phase-change contrast 
agents in vivo. These sequences allow for new perfusion measurements based on 
microbubble wash-out as well as providing a tool for measuring and optimizing the in vivo 
performance of PCCAs as a function of formulation. PCCA-based contrast-enhanced 
imaging may open the possibility of new diagnostic and theranostic applications based on 
PCCA technology.
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Imaging and activation sequence. A free imaging state was used to monitor the breathing 
cycle prior to a manually triggered transition to the pre-activation imaging state. Pre-
activation imaging was followed by a return to the free imaging state. After alignment with 
the breathing cycle, a transition to the activation sequence was manually triggered. A period 
of post-activation imaging immediately followed the activation sequence. In these studies, 
images were reconstructed offline after all imaging and data transfer was complete.
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Representative distributions of contrast agents used in this study. A) DFB microbubbles had 
a mean diameter of 1.00 ± 0.89 µm and a mode size of 0.62 µm. B) Droplets created by 
condensing DFB and OFP microbubbles produced sub-micron distributions. DFB droplets 
had a mean diameter 166 ± 59 nm and a mode of 141 nm, while OFP droplets had a smaller 
mean diameter of 154 ± 64 nm and a mode of 110 nm.
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In Vitro activation of DFB droplets. Changes in the magnitude and geometry of the pressure 
focal zones (A) and corresponding microbubble clouds (B) at nine focal locations occur as a 
result of electronically steering the activation pulses. A region of interest can be filled with 
bubbles by the accumulation of discrete microbubble clouds (C). Spacing the focal locations 
closer results in a more uniform field of bubbles (D).
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Example overlays of B-mode (grey scale) ultrasound scans and contrast-specific pulse-
inversion scans (green scale) for each contrast agent tested. In all images, the pulse-inversion 
scans have been manually cropped to the borders of the kidney region to illustrate 
differences in signal within the kidney. The first column displays the agent-free case (pre-
injection), and the second column corresponds to the pre-activation imaging (after injection 
but before activation). DFB droplets produced no significant increase in contrast after 
injection, but once activated exhibited a ‘patterned’ contrast appearance with lower mean 
contrast compared to microbubbles. OFP droplets, in comparison, exhibited some ‘flashing’ 
in the pre-activation state as a result of unwanted activation, and generated uniform contrast 
with a higher mean value than microbubbles after the activation sequence. The level of OFP 
activation was high enough to produce shadowing deep within the kidney at early time 
points.
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Examples of contrast measurements taken for individual animals administered A) DFB and 
B) OFP droplets. The mean value of the contrast enhancement increased over a short period 
following the vaporization pulse and then decreased as agents washed out of the kidney 
imaging plane. For OFP droplets, spikes in the 1 minute pre-activation capture are visible 
caused by unwanted vaporization.
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Maximum dB enhancement relative to the mean of the agent-free baseline for A) 
microbubbles after injection and B) droplets after application of a vaporization sequence. 
The mean signal within the manually placed ROI showed that microbubbles produced a high 
degree of contrast initially that cleared by the 15 minute mark. Contrast generated by 
activation of OFP was initially greater than DFB and microbubbles, but decayed more 
rapidly than DFB due to droplet instability. Contrast generation variability in the early time 
points is largely due to animal-to-animal differences in attenuation and aberration.
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Change in dB enhancement relative to the mean of the agent-free baseline. A) Initially, the 
pre-activation signal value is zero-mean, but shifts upward on the order of 0.5 dB over the 
test period. Similarly, B) the maximum value produced in the video sequence shifts on the 
order of 0.5 to 1 dB during the test period. It is expected that these changes are due to 
accumulated shifts in animal positioning over the period. Also visible in A) and B) is the 
high contrast produced by unwanted activation of OFP droplets at the 1 minute time point.
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Maximum contrast enhancement over the mean of the agent-free baseline normalized to the 
maximum value produced by each animal for A) microbubbles and B) droplets. DFB 
decayed at a significantly slower rate than OFP and microbubbles, resulting in contrast 
production half-lives on the order of 3-fold longer than microbubbles and OFP droplets. 
Shown in solid lines are the exponential curve fits to the grouped data, with 95% confidence 
intervals in dashed lines.
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Calculated percentage of kidney pixels exceeding the agent-free baseline threshold value for 
the different contrast agents at the 1 minute time point. Contrast generated by the activation 
of OFP filled a greater percentage of the kidney than a microbubble injection, while 
activation of DFB droplets produced an irregular contrast generation pattern and filled less 
of the kidney.
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Table 2
In vivo pressure estimations based on a simple tissue attenuation model.










B-mode 0.50 0.27 0.09
Pulse Inversion 0.50 0.43 0.14
Estimated In Vivo Activation Pressures
Description Axial Location (cm) PNP Value (MPa) Mechanical Index
Start of Kidney 0.30 3.70 1.65
Maximum PNP 0.85 4.50 2.01
End of Kidney 1.00 4.20 1.89
End of Activation ROI 1.20 3.80 1.70
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